References

mrj

Современная ревматология

Modern Rheumatology Journal

1996-70122310-158X

IMA-PRESS, LLC

10.14412/1996-7012-2008-469

mrj-154

Research Article

Статьи

Articles

Варфарин в терапии антифосфолипидного синдрома

Varfarin v terapii antifosfolipidnogo sindroma

Решетняк

Т. М.

Reshetnyak

T M

Kondrat'eva

L V

Kondrat'eva

L V

Штивельбанд

И. В.

Shtivel'band

I B

Насонов

Евгений Львович

Nasonov

E L

2008

11042008

№2 (2008)

2031

2008

Решетняк Т.М., Kondrat'eva L.V., Штивельбанд И.В., Насонов Е.Л.

Reshetnyak T.M., Kondrat'eva L.V., Shtivel'band I.B., Nasonov E.L.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://mrj.ima-press.net/mrj/article/view/154

Описаны фармакокинетика, фармакодинамика и мониторинг терапии варфарином. Рассмотрены вопросы повышенной чувствительности части пациентов к варфарину, а именно ассоциация избыточной гипокоагуляции с мутациями в гене цитохрома Р450 CYP2C9*2 И CYP2C9*3. Суммированы данные литературы о применении варфарина у больных с антифосфолипидным синдромом (АФС). Представлены данные, касающиеся интенсивности антикоагулянтной терапии при АФС. Приведены рекомендации и комментарии, основанные на собственном опыте ведения больных с АФС.

Opisany farmakokinetika, farmakodinamika i monitoring terapii varfarinom. Rassmotreny voprosy povyshennoy chuvstvitel'nosti chasti patsientov k varfarinu, a imenno assotsiatsiya izbytochnoy gipokoagulyatsii s mutatsiyami v gene tsitokhroma R450 CYP2C9*2 I CYP2C9*3. Summirovany dannye literatury o primenenii varfarina u bol'nykh s antifosfolipidnym sindromom (AFS). Predstavleny dannye, kasayushchiesya intensivnosti antikoagulyantnoy terapii pri AFS. Privedeny rekomendatsii i kommentarii, osnovannye na sobstvennom opyte vedeniya bol'nykh s AFS.

References1

<div>Hughes G.R.V. Trombosis, abortion, cerebral disease and lupus anticoagulant. BMJ 1983; 187: 1088-89.Hughes G.R.V., Harris E.N., Charavi A.E. The anti-cardiolipin syndrome. J. Rheumatol 1986; 13: 486-9.Насонов Е.Л. Антифосфолипидный синдром: клиническая и иммунологическая характеристика. Клин мед 1989; 1: 5-13.Насонов Е.Л. Антифосфолипидный синдром. М.: Литтерра 2004; 379.Алекберова З.С., Решетняк Т.М., Кошелева Н.М. и др. Антифосфолипидный синдром при системной красной волчанке: оценка диагностических и классификационных критериев. Клин мед 1996; 6: 39-42.Asherson R.A., Baguley E., Hughes G.R.V. Antiphospholipid syndrome: five years follow-up. Ann Rheum Dis 1991; 50: 805-10.Myakis S., Lockshin M.D., Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospho-lipid syndrome. J Thromb Haemost 2006; 4: 295-306.Wood A. Drug therapy. N Engl J Med 1994; 330: 1287-93.Rosove M.H., Brewer PM.C. Antiphospholipid thrombosis: dinical course after the first thrombotic event in 70 patients. Ann Int Med 1992; 117: 303-8.Derksen R.H.W.M., de Groot Ph.G., Kater L. et al. Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis 1993; 52: 689-92.Khamashta M.A., Cuadrado M.J., Mujic F et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993-7.Krnic-Barrie S., O'Connor C.R., Looney S.W et al. A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of influencing recurrent thrombosis. Arch Intern Med 1997; 157:2101-08.Linkins L.A., Weitz J.I. New anticoagulants. Semin Thromb Hemost 2003; 29: 619-31.Лечение оральными антикоагулянтами. Рекомендации Всероссийской ассоциации по изучению тромбозов, геморрагий и патологии сосудов им. А.А. Шмидта - Б.А. Кудряшова. М.: РКИ Соверо пресс 2002; 36 с.Лечение оральными антикоагулянтами. Методические рекомендации Всероссийской ассоциации по изучению тромбозов, геморрагий и патологии сосудов им. А.А. Шмидта - Б.А. Кудряшова. Сост. Т.В. Козлова. Под ред. Л.Б. Лазебника и И.Н. Бокарева. М.: Издатель Е.Разумова 2003; 28 с.Palkimas M.P, Skinner H.M., Gandhi P.J. et al. Polymorphisms induced sensitivity to warfarin: a review of the literature. Journal of Thrombosis and Thrombolysis 2003; 15: 205-12.Aithal G.P., Day C.P., Kesteven P.J. et al. Association of polymorphisms in cytochrome P450 CYP2C9 withwarfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717-9.Ansell J., Hirsh J., Poller L. et al. The pharmacology and management of the vitamin K antagonists: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 204-33.Takahashi H., Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 2001; 40: 587-603Hirsh J., Fuster V., Ansell J. et al. American Heart Association/American College of Cardiology Foundation Guide to warfarin therapy . Circulation 2003; 107: 1692-711.Wessler S., Gitel S.N. Warfarin: from bedside to bench. N Engl Med 1984; 311: 645-52.Zivelin A., Rao L.V., Rapaport S.I. Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual pto-coagulant vitamin-K dependent clotting factors. J Clin Invest 1993; 92: 2131-40.Patel P., Weitz J., Brooker L.A. et al. Decreased thrombin activity of fibrin clots prepared in cord plasma compared to adult plasma. Pediatr Res 1996; 39: 826-30.Esmon C. T. Molecular events that control the protein C anticoagulant pathway. Thromb Haemost 1993; 70: 29-35.Weitz J.I., Hudoba M., Massel D. et al. Clot- bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inac-tivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-91.Bajzar L., Manuel R., Nesheim M.E. Purification and characterization of TAFI, a throm-bin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-84.Furie B., Diuguid C.F., Jacobs M. et al. Randomized prospective trial comparing the native pro-thrombin antigen with the prothrombin time for monitoring anticoagulant therapy. Blood 1990; 75: 344-9.Moll S., Ortel T.L. Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med 1997; 127: 177-85.Le D.T., Weibert R.T., Sevilla B.K. et al. The international normalized ratio (INR) for monitoring warfarin therapy: reliability and relation to other monitoring methods. Ann Intern Med 1994; 120: 552-8.Lind S.E., Callas P.W., Golden E.A. et al. Plasma levels of factors II, VII and X and their relationship to the international normalized ratio during chronic warfarin therapy. Blood Coagul Fibrinolysis 1997; 8: 48-53.Kornberg A., Francis C.W., Pellegrini V.D. et al. Comparison of native prothrombin antigen with the prothrombin time for monitoring oral anticoagulant prophylaxis. Circulation 1993; 88: 454-60.Kasthuri R.S., Roubey R.A. Warfarin and the antiphospholipid syndrome: does one size fit all? Arthritis Rheum 2007; 57(8, Dec. 15): 1346-47.Wells P.S., Holbrook A.M., Crowther N.R. et al. Interactions of warfarin with drugs and food. Ann Intern Med 1994; 121: 676-83.Чуваева А.В., Балоян Г.М., Зайтман Е.В. и др. Диета и варфаринотерапия. Тромбоз, гемостаз и реология 2004; 1: 73-74.Readman A. Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing. Pharmacotherapy 2001; 21: 235-41.Bhasker C.R., Miners J.O., Coulter S. et al. Allelic and functional variability of cytochrome P450 2C9. Pharmacogenetics 1997; 7: 51-8.Lee C.R., Goldstein J.A., Pieper J.A. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human date. Pharmacogenetics 2002; 12: 251-63.Taube J., Halsall D., Baglin T. Influence of cytochrome P450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000; 96: 1816-19.Higashi M., Veenstra D., Midori Kondo L. et al. Association between CYP2C9 genetic variants and anticoagulation - related outcomes during warfarin therapy. JAMA 2002; 287: 1690-98.Joffe H.V., Xu R., Johnson F.B. et al. Warfarin dosing and cytochrome P450 2C9 polymorphisms. Thromb Haemost 2004; 91: 1123-28.Bodin L., Verstuyft C., Tregouet D.A. et al. Cytochrome P4502C9 (CYP2C9) and vitamin K epox- ide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 2005; 106: 135-40.Ruiz-Irastorza G., Hunt B.J., M.A.Khamashta. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum 2007; 57(8, Dec.15): 1487-95.Munoz-Rodriguez F.J. Font J. Cervera et al. Clinical study and follow-up of 100 patients with the antiphospholipid syndrome. Semin Arthritis Rheum 1999; 29: 182-90.Ruiz-Irastorza G., Khamashta K.A., Hunt B.J. et al. Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: an analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3,5. Arch Intern Med 2002; 162: 1164-9.Witkowsky A.K., Downing J., Blackburn J. et al. Warfarin-related outcomes in patients with antiphos-pholipid antibody syndrome managed in an anticoagulation clinic. Thromb Haemost 2006; 96: 137-141.Parandoni P., Simioni P., Girolami A. Antiphospholipid antibodies, recurrent thromboem-bolism, and intensity of warfarin anticoagulation [letter]. Thromb Haemost 1996;75:859.Rance A., Emmerich J., Fiessinger J.N. Anticardiolipin antibodies and recurrent thromboembolism [letter]. Thromb Haemost 1997; 77:221-2.Levine S.R., Brey R.L., Tilley B.C. et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004; 291: 576-84.Levine M.N., Rascobe G., Landefeld S. et al. Hemorrhagic complications of anticoagulant treatment. Chest 2001;119: 108-21.Brey R.L., Levine S.R. APL and the brain: treatment (abstract). Lupus 2002; 9: 559.Ginsberg J.S., Wells P.S., Brill-Edwards P et al. Antiphospholipid antibodies and venous throm- boembolism. Blood 1995; 86: 3685-91.Ames P.R.J., Ciampa A., Grandone E. et al. Conventional oral anticoagulation (INR 2-3) effectively prevents rethrombosis in primary antiphospholipid antibody syndrome (abstract). Lupus 2002; 9: 624.Crowther M.A., Ginsberg J.S., Julian J. et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 1133-8.Finazzi G., Marchioli R., Brancaccio V. et al. A randomized clinical trial of high intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). Thromb Haemost 2005; 3: 848-53.Kearon C., Gent M., Hirsh J. et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 901-7.Hirsh J., Kearon C., Ginsberg J. Duration of anticoagulant therapy after first episode of venous thrombosis in patients with inherited thrombophilia. Arch Intern Med 1997;157: 2174-7.Palareti G., Leali N., Cocheri S. et al. Bleeding complications of oral anticoagulant treatment: an inception - cohort, prospective collaborative study (ISCOAT). Italian study on complications of oral anticoagulant therapy. Lancet 1996; 348: 423-8.Landefeld C.S., Beyth R.J. Anticoagulant - related bleeding: clinical epidemiology, prediction. Am J Med 1993;95: 315-28. Van der Meer F.J., Rosendaal F.R., Vandenbroucke J.P., Briet E. Bleeding complications in oral anticoagulant therapy. An analisis of risk factors. Arch Intern Med. 1993; 153: 1557-62.McCrae K.R. Antiphospholipid antibody associated thrombosis: a consensus for treatment. Lupus 1996; 5: 560-70.Giron-Gonzales J.A.,Garcia del Rio E., Rodriguez C. et al. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody procpectiva analysis of 404 individuals. J Rheumtol 2004; 31: 1560-7.Решетняк Т.М., Кондратьева Л.В., Патрушев Н.Л. и др. Варфарин при лечении антифосфолипидного синдрома. Тер арх 2007;5: 47-54.Кондратьева Л.В., Решетняк Т.М., Патрушева Н.Л. и др. Влияние полиморфизма цитохрома Р450 на эффективность и безопасность терапии варфарином у пациентов с антифосфолипидным синдромом. Научно-практ ревматол 2006; 4:63-9.Beyth R.J., Quinn L., Landefeld C.S. A multi-component intervention to prevent major bleeding complications in older patients receiving warfarin: a randomized, controlled trial. Ann Intern Med 2000; 133: 687-95.</div>

The authors declare that there are no conflicts of interest present.